Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia

This publication has 30 references indexed in Scilit:

• Lack of Effect of Food on the Bioavailability of a New Ketolide Antibacterial, Telithromycin
  Scandinavian Journal of Infectious Diseases, 2002
• Telithromycin
  Drugs, 2001
• Pharmacokinetics of the New Ketolide Telithromycin (HMR 3647) Administered in Ascending Single and Multiple Doses
  Antimicrobial Agents and Chemotherapy, 2001
• Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults
  Clinical Infectious Diseases, 2000
• Canadian Guidelines for the Initial Management of Community-Acquired Pneumonia: An Evidence-Based Update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
  Clinical Infectious Diseases, 2000
• CHANGING PATTERNS OF ETIOLOGY AND RESISTANCE IN COMMUNITY-ACQUIRED RESPIRATORY TRACT INFECTIONS
  Infectious Diseases in Clinical Practice, 1998
• Once‐Daily Sparfloxacin Versus High‐Dosage Amoxicillin in the Treatment of Community‐Acquired, Suspected Pneumococcal Pneumonia in Adults
  Clinical Infectious Diseases, 1998
• Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996–1997 respiratory season
  Diagnostic Microbiology and Infectious Disease, 1997
• A comparative study of dirithromycin and erythromycin in bacterial pneumonia
  Journal of Infection, 1994
• Evaluation of New Anti-Infective Drugs for the Treatment of Respiratory Tract Infections
  Clinical Infectious Diseases, 1992